Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Diabetes | Research article

Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid–femoral pulse wave velocity in hemodialysis patients: a cross sectional study

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Cardiovascular morbidity and mortality are highly prevalent in patients with end-stage renal disease, and osteoprotegerin (OPG) may be an important link between bone loss and vascular calcification. This study was conducted to evaluate the relationship between central arterial stiffness and serum OPG levels in hemodialysis (HD) patients.

Methods

Blood samples were collected from 120 HD patients, and the carotid–femoral pulse wave velocity (cfPWV) value was measured using a validated tonometry system. The cfPWV value of > 10 m/s was used to define the high artery stiffness group. Serum OPG levels were analyzed categorically into tertiles.

Results

Of the 120 HD patients, 53 (44.2%) were defined as the high arterial stiffness group, who had higher values of systolic blood pressure (p = 0.038), serum calcium (p = 0.007), and OPG (p <  0.001) levels and a higher prevalence of diabetes mellitus (DM, p = 0.001). Increasing tertiles of serum OPG levels were significantly associated with greater height (p = 0.011), male gender (p = 0.008), higher cfPWV values (p = 0.020), and lower intact parathyroid hormone (iPTH, p = 0.049) levels. Multivariable linear regression analysis showed that cfPWV value was independently associated with DM (β = 1.83, p = 0.008) and increasing tertiles of serum OPG levels (β = 0.89 and 1.63 for tertile 2 and tertile 3, respectively, p for trend = 0.035) in HD patients. Multivariable logistic regression analysis revealed that, in addition to age, DM, low iPTH levels, and high serum calcium levels, increasing tertiles of serum OPG levels (OR = 5.34 for tertile 2; OR = 7.06 for tertile 3; p for trend = 0.002) were an independent predictor of high arterial stiffness in HD patients. Serum calcium levels positively correlated with cfPWV value only in the highest OPG tertile group (r = 0.408, p = 0.009).

Conclusion

A positive association was detected between serum OPG levels and central arterial stiffness in HD patients, and patients with high serum OPG levels may have greater influence of calcium load on central arterial stiffening.
Literature
1.
go back to reference Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.CrossRef Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.CrossRef
2.
go back to reference de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. Jama. 2009;302(16):1782–9.CrossRef de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. Jama. 2009;302(16):1782–9.CrossRef
3.
go back to reference Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–23.PubMed Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–23.PubMed
4.
go back to reference Chen NX, Moe SM. Pathophysiology of vascular calcification. Current Osteoporosis Reports. 2015;13(6):372–80.CrossRef Chen NX, Moe SM. Pathophysiology of vascular calcification. Current Osteoporosis Reports. 2015;13(6):372–80.CrossRef
5.
go back to reference Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016;31(1):31–9.CrossRef Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016;31(1):31–9.CrossRef
6.
go back to reference Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213–6.CrossRef Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213–6.CrossRef
7.
go back to reference Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C. The role of osteoprotegerin in the crosstalk between vessels and bone: its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther. 2018;182:115–32.CrossRef Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C. The role of osteoprotegerin in the crosstalk between vessels and bone: its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther. 2018;182:115–32.CrossRef
8.
go back to reference Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002;39(3):525–32.CrossRef Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002;39(3):525–32.CrossRef
9.
go back to reference Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605.CrossRef Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605.CrossRef
10.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRef Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRef
11.
go back to reference London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001;38(3):434–8.CrossRef London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001;38(3):434–8.CrossRef
12.
go back to reference Wang JH, Lee CJ, Chen ML, Yang CF, Chen YC, Hsu BG. Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients. J Clin Hypertens (Greenwich). 2014;16(4):301–8.CrossRef Wang JH, Lee CJ, Chen ML, Yang CF, Chen YC, Hsu BG. Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients. J Clin Hypertens (Greenwich). 2014;16(4):301–8.CrossRef
13.
go back to reference Massry SG, Coburn JW, Chertow GM, Hruska K, Langman C, Malluche H, Martin K, LM MC, JT MC, Moe S, Salusky IB. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201. Massry SG, Coburn JW, Chertow GM, Hruska K, Langman C, Malluche H, Martin K, LM MC, JT MC, Moe S, Salusky IB. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201.
14.
go back to reference Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.CrossRef Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.CrossRef
15.
go back to reference Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–8.CrossRef Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–8.CrossRef
16.
go back to reference Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J, Unt E, Lieberg J, Kals J. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens. 2010;23(6):586–91.CrossRef Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J, Unt E, Lieberg J, Kals J. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens. 2010;23(6):586–91.CrossRef
17.
go back to reference Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006;47(9):1850–7.CrossRef Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006;47(9):1850–7.CrossRef
18.
go back to reference Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2612–9.CrossRef Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2612–9.CrossRef
19.
go back to reference Pateinakis P, Papagianni A, Douma S, Efstratiadis G, Memmos D. Associations of fetuin-a and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol. 2013;14:122.CrossRef Pateinakis P, Papagianni A, Douma S, Efstratiadis G, Memmos D. Associations of fetuin-a and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol. 2013;14:122.CrossRef
20.
go back to reference Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol. 2005;63(5):594–8.CrossRef Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol. 2005;63(5):594–8.CrossRef
21.
go back to reference Sigrist MK, McIntyre CW, Levin A, Er L. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009;24(10):3157–62.CrossRef Sigrist MK, McIntyre CW, Levin A, Er L. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009;24(10):3157–62.CrossRef
22.
go back to reference Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006;17(1):262–70.CrossRef Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006;17(1):262–70.CrossRef
23.
go back to reference Lee JE, Kim HJ, Moon SJ, Nam JS, Kim JK, Kim SK, Yun GY, Ha SK, Park HC. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients. Korean J Intern Med. 2013;28(6):668–77.CrossRef Lee JE, Kim HJ, Moon SJ, Nam JS, Kim JK, Kim SK, Yun GY, Ha SK, Park HC. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients. Korean J Intern Med. 2013;28(6):668–77.CrossRef
24.
go back to reference London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul M-C. Association of Bone Activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827–35.CrossRef London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul M-C. Association of Bone Activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827–35.CrossRef
25.
go back to reference Persy V, D’Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009;15(9):405–16.CrossRef Persy V, D’Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009;15(9):405–16.CrossRef
26.
go back to reference London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul M-C. Arterial calcifications and bone Histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943–51.CrossRef London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul M-C. Arterial calcifications and bone Histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943–51.CrossRef
27.
go back to reference Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932–43.CrossRef Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932–43.CrossRef
28.
go back to reference Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14(5):475–86.CrossRef Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14(5):475–86.CrossRef
29.
go back to reference Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y. Diabetes MellitusAortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 2001;12(10):2117–24.PubMed Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y. Diabetes MellitusAortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 2001;12(10):2117–24.PubMed
30.
go back to reference Aoun S, Blacher J, Safar ME, Mourad JJ. Diabetes mellitus and renal failure: effects on large artery stiffness. J Hum Hypertens. 2001;15:693.CrossRef Aoun S, Blacher J, Safar ME, Mourad JJ. Diabetes mellitus and renal failure: effects on large artery stiffness. J Hum Hypertens. 2001;15:693.CrossRef
31.
go back to reference Cameron JD, Bulpitt CJ, Pinto ES, Rajkumar C. The aging of elastic and muscular arteries: a comparison of diabetic and nondiabetic subjects. Diabetes care. 2003;26(7):2133–8.CrossRef Cameron JD, Bulpitt CJ, Pinto ES, Rajkumar C. The aging of elastic and muscular arteries: a comparison of diabetic and nondiabetic subjects. Diabetes care. 2003;26(7):2133–8.CrossRef
32.
go back to reference Strain WD, Chaturvedi N, Dockery F, Shiff R, Shore AC, Bulpitt CJ, Rajkumar C. Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors. Am J Hypertens. 2006;19(9):889–96.CrossRef Strain WD, Chaturvedi N, Dockery F, Shiff R, Shore AC, Bulpitt CJ, Rajkumar C. Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors. Am J Hypertens. 2006;19(9):889–96.CrossRef
Metadata
Title
Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid–femoral pulse wave velocity in hemodialysis patients: a cross sectional study
Publication date
01-12-2019
Keyword
Diabetes
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1374-2

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue